Outcome of Long-term Maintenance Steroid Therapy Cessation in Patients With Autoimmune Pancreatitis: A Prospective Study

Objective: To predict the duration of steroid maintenance therapy required to achieve good prognosis in patients with autoimmune pancreatitis. Patients and Methods: The study sample comprised 21 patients with autoimmune pancreatitis who met the following criteria: (1) they received steroid therapy (ST) for at least 3 years without clinical relapse; and (2) immunoglobulin (Ig) G<1600 mg/dL was observed in the past year with a prednisolone maintenance dose ⩽5 mg. All patients could be diagnosed with international consensus diagnostic criteria. Patients were prospectively followed up after tapering and cessation of steroids. Clinical relapse was defined as the need to resume ST. Serological relapse was defined as having an IgG level of >1600 mg/dL. Results: During the 43-month (range, 19 to 48 mo) follow-up period, clinical relapse occurred in 10 patients: pancreatic lesion in 4; coronary lesion in 2; submandibular lesion in 1; both pulmonary and renal lesions in 1; pulmonary, retroperitoneal, and submandibular lesions in 1; and bronchial asthma in 1. Serological relapse was observed in 12 patients. Although clinical and serological relapse occurred concomitantly in 3 patients, serological relapse preceded clinical relapse in 4 patients. Five patients experienced serological relapse alone, and no clinical or serological relapse occurred in 6 patients. According to Cox proportional hazard analysis, the duration of ST before tapering was a significant predictive parameter (hazard ratio, 0.969/month; 95% confidence interval, 0.940-0.998; P=0.038). Conclusions: ST cessation resulted in a high rate of clinical relapses, even in patients with long-term maintenance therapy. Therefore, it appears desirable to continue steroid maintenance therapy for a period >3 years to prevent relapse.

[1]  Jimin Han Treatment of Autoimmune Pancreatitis , 2017 .

[2]  A. Yen,et al.  Coronary periarteritis in a patient with multi-organ IgG4-related disease. , 2015, Journal of radiology case reports.

[3]  S. Chari,et al.  Treatment: Immunomodulatory drugs and rituximab , 2015 .

[4]  L. Buja,et al.  Sudden cardiac death due to coronary artery involvement by IgG4-related disease: a rare, serious complication of a rare disease. , 2014, Archives of pathology & laboratory medicine.

[5]  Y. Makino,et al.  A suspected case of coronary periarteritis due to IgG4-related disease as a cause of ischemic heart disease , 2014, Forensic Science, Medicine, and Pathology.

[6]  P. Gutierrez,et al.  Sudden coronary death due to IgG4-related disease. , 2013, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[7]  R. D. de Man,et al.  Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. , 2013, Journal of hepatology.

[8]  J. Tanigawa,et al.  Immunoglobulin G4-related coronary periarteritis in a patient presenting with myocardial ischemia. , 2012, Human pathology.

[9]  K. Maemura,et al.  Mass lesions surrounding coronary artery associated with immunoglobulin G4-related disease. , 2012, Journal of cardiology cases.

[10]  S. Kawa,et al.  The Utility of Serum IgG4 Concentrations as a Biomarker , 2012, International journal of rheumatology.

[11]  M. Kondo,et al.  Three cases of bronchial asthma preceding IgG4-related autoimmune pancreatitis. , 2012, Allergology international : official journal of the Japanese Society of Allergology.

[12]  K. Amano,et al.  A case of multiple giant coronary aneurysms and abdominal aortic aneurysm coexisting with IgG4-related disease. , 2012, Internal medicine.

[13]  N. Sasahira,et al.  Evaluation of Cell-Free DNA in Plasma and Serum as Early Predictors of Severity in Acute Pancreatitis , 2011, Pancreas.

[14]  Y. Shinomura,et al.  Mikuliczs Disease and its Extraglandular Lesions , 2011 .

[15]  Myung-Hwan Kim,et al.  International Consensus Diagnostic Criteria for Autoimmune Pancreatitis: Guidelines of the International Association of Pancreatology , 2011, Pancreas.

[16]  K. Tobe,et al.  Deforming arthropathy in a patient with IgG4‐related systemic disease: Comment on the article by Stone et al , 2011, Arthritis care & research.

[17]  T. Shimosegawa,et al.  Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP , 2010, Journal of Gastroenterology.

[18]  N. Sasahira,et al.  Endoscopic evaluation of factors contributing to intrapancreatic biliary stricture in autoimmune pancreatitis. , 2010, Gastrointestinal endoscopy.

[19]  T. Shimosegawa,et al.  Standard steroid treatment for autoimmune pancreatitis , 2009, Gut.

[20]  R. Pezzilli,et al.  Usefulness of serum IgG4 in the diagnosis and follow up of autoimmune pancreatitis: A systematic literature review and meta‐analysis , 2009, Journal of gastroenterology and hepatology.

[21]  T. Shimosegawa,et al.  Asian diagnostic criteria for autoimmune pancreatitis: consensus of the Japan-Korea Symposium on Autoimmune Pancreatitis , 2008, Journal of Gastroenterology.

[22]  B. Petersen,et al.  Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. , 2008, Gastroenterology.

[23]  S. Chari,et al.  Optimising corticosteroid treatment for autoimmune pancreatitis , 2007, Gut.

[24]  N. Sasahira,et al.  Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment , 2007, Gut.

[25]  A. Montano‐Loza,et al.  Improving the End Point of Corticosteroid Therapy in Type 1 Autoimmune Hepatitis to Reduce the Frequency of Relapse , 2007, The American Journal of Gastroenterology.

[26]  K. Shimizu,et al.  Long-term outcome of autoimmune pancreatitis after oral prednisolone therapy. , 2006, Internal medicine.

[27]  N. Sasahira,et al.  High‐rate pulmonary involvement in autoimmune pancreatitis , 2006, Internal medicine journal.

[28]  S. Kawa,et al.  High Prevalence of Hypothyroidism in Patients with Autoimmune Pancreatitis , 2005, Digestive Diseases and Sciences.